Agra

Researchers are evaluating the safety and effectiveness of centhaquine citrate (LYFAQUIN193), a new drug designed to treat hypovolemic shock, which is a serious condition caused by severe blood or fluid loss. This phase IV, open-label, multi-center study involves adult patients aged 18 years or older who are experiencing hypovolemic shock with low blood pressure and elevated blood lactate levels. Centhaquine has shown promising results in animal models by improving blood pressure, cardiac output, and reducing mortality through its action on specific adrenergic receptors. Participants will receive centhaquine alongside standard shock treatments such as fluid resuscitation, vasopressors, and endotracheal intubation. The drug will be given intravenously at a dose of 0.01 mg/kg in 100 mL of normal saline over one hour. If blood pressure remains low, an additional dose may be given after 4 hours, with a maximum of three doses within 24 hours. Centhaquine administration can continue for up to two days after enrollment, with close monitoring throughout their hospital stay. During the study, patients will be monitored until discharge or for up to seven days from enrollment. Researchers will assess safety by tracking adverse and serious adverse events, as well as efficacy by measuring blood pressure, lactate levels, base deficit, and survival rates. Statistical analyses will compare patient outcomes, and the results will be presented with detailed data summaries to evaluate the drug's safety and benefits when added to standard care for hypovolemic shock.

Researchers are evaluating the Balanced Progressive Intensity Training (BPIT) 5-Line Principle in healthy adults aged 18 to 65 years. This multi-site, prospective, single-arm study lasts 5 weeks and aims to measure changes in functional movement efficiency, joint mobility, postural control, strength, and heart-rate variability. The training method progresses through five intensity levels based on anatomical landmarks and ground reaction force to improve physical fitness while monitoring safety and individual overload signs. Participants will undergo supervised BPIT sessions 3 to 5 times per week for 5 weeks. The training intensity moves through five levels: Ground-Based (Low), Knee-Level (Low-Moderate), Standing (Moderate), Head-Level (Moderate-High), and Plyometric (High-Impact). This progressive method is designed to promote neuromuscular adaptation and strength improvement across these stages. During the study, researchers will assess functional movement screen scores, Y-Balance reach distance, strength via 1-RM or estimates, heart-rate variability at rest, joint range of motion, and postural sway. These measures are taken at baseline, weekly, and at the study's end (Week 5). Safety is monitored by tracking any training-related discomfort or minor injuries. Overall participation involves attending multiple supervised sessions and completing assessments over the 5-week period.

Researchers are evaluating the effectiveness and safety of two oral drug combinations, Bemnifosbuvir-Ruzasvir (BEM/RZR) and Sofosbuvir-Velpatasvir (SOF/VEL), in adults with chronic Hepatitis C virus (HCV) infection. This Phase 3 trial compares these treatments to determine which is better at reducing the virus in the blood. Participants include adults aged 18 to 85 years, including those with compensated liver cirrhosis, and some with controlled HIV-1 infection under specific treatment conditions. Participants will receive either BEM/RZR tablets once daily for 8 weeks if they do not have cirrhosis, or for 12 weeks if they have compensated cirrhosis. Those in the comparison group will take SOF/VEL tablets once daily for 12 weeks. The study is randomized, controlled, and open-label, meaning both participants and researchers know which treatment is given. During the study, researchers will monitor patients to see how many achieve very low levels of HCV RNA in their blood by week 24. The study will include regular medical assessments, safety monitoring, and evaluation of treatment adherence. Participants will be followed from the start of treatment until 24 weeks later to assess outcomes and any side effects.